
|Articles|May 1, 2013
Targeted Therapies in Oncology
- May 2013
- Volume 2
- Issue 3
Full Version of the May 2013 Issue
Full version of the May 2013 Targeted Therapy News
Advertisement
Targeted Therapy Newscovers the most important developments in cancer care today, personalized medicine and targeted therapies. The publication is strongly committed to providing oncology healthcare professionals the information and resources they need to deliver the best possible treatment to their patients
This issue features articles on:
- Key targeted trials being presented at ASCO
- Nongenetic mechanisms of cancer cell diversity and treatment response
- Platinum resistance in ovarian cancer
- HER2-targeted agents in NSCLC
Articles in this issue
over 12 years ago
Bundled Payment: Practice Savior or Killer?over 12 years ago
Notch Holds Promise, but Presents Obstacles as Cancer Targetover 12 years ago
Spotlight on Novel Agents in Early Developmentover 12 years ago
Treating Elderly Patients With CLLover 12 years ago
Biomarkers Still Needed in Prostate CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5










































